News zum Sektor Gesundheit aus Schweiz

 

Its revolutionary CASGEVY treatment could be a sign of what's to come....

Basel, June 3, 2026 – Novartis presented today new Cosentyx® (secukinumab) data in polymyalgia rheumatica (PMR) demonstrating a statistically significant, clinically meaningful difference in sustained remission rates vs placebo and significant steroid sparing8. Published in the New England Journal of Medicine and simultaneously presented at the 2026 European Alliance of Associations for Rheumatology (EULAR) Congress, Phase III REPLENISH data showed that the effect of Cosentyx treatment was sustained through week 52 in this investigational use8....

AC Immune (ACIU) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Pharma - Roche ist eine Zusammenarbeit mit dem US-Biotechunternehmen Ideaya Biosciences eingegangen....

Er befasst sich jeden Tag mit einer Vielfalt an Themen und schätzt die Möglichkeit, das Leben von Patienten zu verbessern. Im Interview spricht Raid Sherif, CEO von Oculis, über aktuelle Projekte und was er seinem 20-jährigen Selbst raten würde....

IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma IDEAYA will......

The application seeks approval of giredestrant as an adjuvant treatment for adults with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, stage I to III breast The post Roche's giredestrant secures FDA priority review for breast cancer appeared first on Pharmaceutical Business review....

Eli Lilly's pipeline is an embarrassment of riches....

Um den gesamten Artikel unter 4investors.de zu lesen, klicken Sie bitte auf die Überschrift...

Zürich (www.aktiencheck.de) - Bayer-Chartanalyse der UBS: Die Aktie der Bayer AG (ISIN: DE000BAY0017, WKN: BAY001, Ticker-Symbol: BAYN, NASDAQ OTC-Symbol: BAYZF) hat gestern weiter nachgegeben und ist dabei auf ein neues Jahrestief gefallen, wie aus der Veröffentlichung "KeyInvest DailyTrader" der UBS hervorgeht. [mehr]...

GENEVA, June 3, 2026 /PRNewswire/ -- MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today published the invitation to its 2026 Annual General Meeting (AGM), which will be held on June 25, 2026,......

"Analysten schätzen das US-Umsatzpotenzial von Zevtera in der Spitze auf etwas über 300 Millionen US-Dollar."...

MindMaze Therapeutics Publishes Invitation to the 2026 Annual General Meeting...

Roche Holding (RHHBY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

RHHBY's giredestrant as an adjuvant treatment for early-stage breast cancer won FDA Priority Review, backed by encouraging phase III data versus standard therapy....

SAN FRANCISCO--(BUSINESS WIRE)--Wayleadr, the category-defining Arrival Platform transforming how people and vehicles access workplaces and parking, today announced a majority growth investment to accelerate the company's next phase of global expansion. Founded in 2016 by entrepreneur Garret Flower, Wayleadr pioneered the Arrival Platform category, helping many of the world's leading enterprises modernize parking, workplace access, and visitor management across global portfolios. Today, the platform powers millions of seamless arrivals annually for organizations including OpenAI, Google, Uber, Novartis, Sanofi, Riot Games, and other leading global enterprises. Under Flower's leadership as Founder & CEO, Wayleadr expanded internationally across 10+ countries, with a strong focus on the US market, becoming one of the most recognized technology platforms in workplace operations. “This is an important milestone for Wayleadr and a reflection of what the team has built over the past several years,” said ...

Nach dem IPO im April 2019 startete Medacta mit Kursen um die 100 CHF an der SIX. Meist ist es ruhig um den Orthopädie-Spezialisten aus dem Tessin, die Aktie zeigt […] Der Beitrag Francesco Siccardi, CEO Medacta: «Die Aktionäre können bis 2030 ein grösseres Unternehmen erwarten» erschien zuerst auf schweizeraktien.net....

SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced the FDA has accepted the company's New Drug Application under Priority Review for giredestrant, an investigational oral selec......